With the Series A financing round, Swiss Nuclides AG was able to raise CHF 2.6 million. Zurich-based Turos Capital AG and private investors were involved. This capital will be used to continue the preclinical and clinical development of the lead molecules.<\/p>
The Aargau start-up develops solutions for personalized cancer diagnostics, prostate cancer and neuroendocrine tumors. This improves the use of positron emission tomography (PET). This reduces cancer diagnosis and radiation exposure for patients to a minimum. With this method, sugar metabolism processes are examined to identify changed tissue structures. The patients take glucose which is linked to a weakly radioactive tracer molecule.<\/p>","protected":false},"excerpt":{"rendered":"
Die Swiss Nuclides AG konnte mit der Serie-A Finanzierungsrunde 2,6 Millionen Franken einnehmen. Beteiligt waren die Z\u00fcrcher Turos Capital AG sowie private Investoren. Dieses Kapital wird f\u00fcr die Fortsetzung der pr\u00e4klinischen und klinischen Entwicklung der Leitmolek\u00fcle eingesetzt.
\nDie Aargauer Jungfirma entwickelt L\u00f6sungen f\u00fcr die personalisierte Krebsdiagnostik, von Prostatakrebs, sowie neuroendokrinen Tumoren. Damit wird der Einsatz der Positronenemissionstomografie (PET) verbessert. Diese reduziert die Krebsdiagnostik und Strahlenbelastung f\u00fcr Patienten auf ein Minimum. Bei dieser Methode werden Zuckerstoffwechselprozesse zur Erkennung ver\u00e4nderter Gewebestrukturen untersucht. Die Patienten nehmen Traubenzucker, der an ein schwach radioaktives Tracer-Molek\u00fcl gekoppelt ist.<\/p>\n","protected":false},"author":2,"featured_media":21656,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_surecart_dashboard_logo_width":"180px","_surecart_dashboard_show_logo":true,"_surecart_dashboard_navigation_orders":true,"_surecart_dashboard_navigation_invoices":true,"_surecart_dashboard_navigation_subscriptions":true,"_surecart_dashboard_navigation_downloads":true,"_surecart_dashboard_navigation_billing":true,"_surecart_dashboard_navigation_account":true,"inline_featured_image":false,"footnotes":""},"categories":[12481,12476],"tags":[12781,12525,12526,13271,13272,12528,13738,13739],"class_list":["post-22139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-en","category-immonews","tag-finanzen-en","tag-immoinvest-en","tag-immonews-en","tag-kapital-en","tag-kapitalerhoehung-en","tag-news-en","tag-swiss-nuclides-en","tag-turos-capital-ag-en"],"acf":{"bild_mit_ki_erstellt_worden":[],"lead":"","autor":"ssp","ort":"Aargau","bildunterschrift":"","bild_im_grid":false,"gallerie":null,"newsim":"","zusammenfassung":""},"featured_image_src":"https:\/\/stage.immo-invest.ch\/wp-content\/uploads\/2021\/06\/finanzen-9-150x150.jpg","_links":{"self":[{"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/posts\/22139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/comments?post=22139"}],"version-history":[{"count":0,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/posts\/22139\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/media\/21656"}],"wp:attachment":[{"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/media?parent=22139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/categories?post=22139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stage.immo-invest.ch\/en\/wp-json\/wp\/v2\/tags?post=22139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}